Compare Moderna, Inc. (MRNA) vs Advanced Drainage Systems Inc (WMS) Price & Performance

Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.

While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.

Advanced Drainage Systems (WMS) trades at $126.36, up 0.22% with a bearish technical signal despite strong fundamental performance. The company reported Q2 2026 EPS of $2.49, beating estimates by 18.6%, continuing a trend of earnings outperformance. Key financial metrics show robust profitability with 14% net income margin and 24.9% ROE, though cash flow turned negative in 2025 due to increased capital investments. Recent news highlights sustainability initiatives and institutional positioning changes.

WMS presents a compelling investment case with consistent earnings beats and strong analyst support ($188.70 price target), but faces near-term technical headwinds and cash flow pressures from aggressive expansion. The stock's current valuation at 21.5x P/E appears reasonable given growth prospects, though investors should monitor execution of NDS integration and capital allocation strategy.